Sohn HK 2022 supports Qvin research

The video discusses a new technology developed by a Women's Health company that allows for at-home self-collection of menstrual blood for health testing. This innovation aims to improve cervical cancer screening, particularly in areas with limited access to medical professionals. The company is currently validating its results in collaboration with Stanford Hospital and plans to scale the technology after ensuring its safety and efficacy. Although not currently fundraising, the company has raised $12.3 million and is focused on FDA approval. The technology also has potential applications for other health conditions, such as diabetes and thyroid issues.

What steps are being taken to validate the results of the technology?

What other health markers could potentially be monitored using this technology?